1. Introduction {#sec1}
===============

Myelodysplastic syndromes (MDS) are characterized by functional abnormalities of hematopoietic lineages. Due to ineffective hematopoiesis, patients with MDS present with cytopenia(s) associated with morphological dysplasia and/or increase in number of blasts, and can progress to acute myeloid leukemia. The laboratory diagnostic strategy in MDS has evolved significantly over the years. Currently the integrated cytogenetic/genetic approach is critical for diagnosis and prognosis of MDS. DNA methylation is a biochemical process that is important for normal development in higher organisms. It involves the addition of a methyl group to the 5 position of the cytosine pyrimidine ring carried out by DNA methyltransferases. It has been shown that MDS patients, especially high-risk MDS, have abnormal hypermethylation of tumor suppressor genes \[[@B1]\].

Our previous works indicated that Chinese herbal formula Qing-Huang powder (containing Realgar As~4~S~4~) is effective in the treatment of myelodysplastic syndrome (MDS) \[[@B3]--[@B5]\]. In the year 2011, we reported that of 124 cases of MDS patients treated with arsenic-containing herbal formula, complete remission and partial remission rate was achieved in 29 (23.4%) patients; hematologic improvement was achieved in 61 (49.2%) patients. The total efficacy rate was 80.6%. The clinical outcome after treatment was closely correlated with WHO Classification of myelodysplastic syndromes, MDS-risk scores, "International Prognostic Scoring System" (IPSS), and cyogenetic abnormality. However the underlined mechanisms remain unclear. To address the value of traditional medicine, efforts are required to delineate how the clinically effective formulae work at the molecular, cellular, and organism levels.

In this paper, using standard cytogenetic analysis (G-banded) and global DNA methylation method (ChIP-on-chip assays), we aimed to determine the effect of arsenic-containing Chinese herbal formula on karyotype status, the genomic methylation level as well as the correlation between aberrant DNA methylation and chromosome aberrations.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Treatment Regimen {#sec2.1}
-----------------------------------

Twenty-five patients enrolled in this study were from outpatient clinics between 2009 and 2011 after giving informed consent. All patients were diagnosed according to WHO classification system (2008) and international prognostic scoring system (IPSS) \[[@B6]\]. The inclusion criteria: measurements of clinical response were defined according to standardized response criteria for myelodysplastic syndromes established by the International Working Group \[[@B7], [@B8]\]; patient had to be 18 to 75 years old; patients must not have received another investigational or approved therapy for MDS within 4 weeks of study enrollment; patients had no history of severe dysfunction of heart, liver, or kidney; all patients provided informed consent before this study. The exclusion criteria: patients had severe adverse effects during treatment; patients were allergic to tested drugs; patients were pregnant, breast-feeding, or had a mental disorder during treatment.

All patients orally took arsenic-containing Qing-Huang powder capsule combined with Bupi Yishen Decoction for 6 months. Qing-Huang powder capsule 0.4 g/day (containing Indigo 0.24 g, and Realgar 0.16 g); Bupi Yishen Decoction once a day, consisting of Sheng-shu-di, Shan-yao, Shan-yu-rou, Dan-pi, Fu-ling, Ze-xie, Bu-gu-zhi, Tu-si-zi, Zhi-shou-wu, Tai-zi-shen, Bai-zhu, Sheng-jiang, Da-zao, Sang-ren, Nu-zhen-zi, and Han-lian-cao were added for the patient with symptoms of Yin deficiency; Suo-yang, Ba-ji-tian, Gu-zhi, Zhi-fu-pian were added for the patient with symptoms of Yang deficiency.

2.2. Detection of Blood Arsenic Concentration {#sec2.2}
---------------------------------------------

After treatment with Qing-Huang powder capsule, arsenic level in peripheral blood was detected by the coupling of high performance liquid chromatography (HPLC) with inductively coupled plasma mass spectrometry (ICP-MS) with the lowest detection limitation of 0.03 ug/L.

2.3. Cytogenetic Analysis {#sec2.3}
-------------------------

Cytogenetic analysis was performed on marrow aspirates according to the standard methods. Chromosome preparations were G-banded using trypsin and Giemsa, and karyotypes were described according to International System for Human Cytogenetic Nomeclature (ICSN) \[[@B9]\]. Major aberrant clone was confirmed by fluorescence in situ hybridization (FISH), probes including CEP8, D5S23-5q31, D7S522-CEP7, and D20S108.

2.4. DNA Methylation and Data Analysis {#sec2.4}
--------------------------------------

Methylation detection was performed using Affymetrix USA GeneChip Human Promoter 1.0 Array according to the manufacturer\'s protocol (detailed protocol can be found at <http://www.affymetrix.com/>). Briefly, bone marrow mononuclear cells from MDS patients were collected before and after treatment. Methylated fraction of DNA was obtained using EpiQuik Methylated DNA Immunoprecipitation Kit (Promega). DNA target was PCR-amplified, fragmented, and terminally labeled. After hybridization, washing, and staining, the chip was scanned following the instructions. Conditions of chips before and after standardization were shown in supplemental Figures  1 and  2 (see Supplementary Material available online at doi:10.1155/2012/969476).

DNA methylation detection was achieved in all 25 patients before treatment, in 14 patients after treatment. DNA methylation information from 5 normal cases traced from NCBI public data Bank served as control \<<http://www.ncbi.nlm.nih.gov/>\>. Patient characteristics are listed in [Table 1](#tab1){ref-type="table"}.

2.5. Data Analysis and Statistics {#sec2.5}
---------------------------------

All data were analyzed using two tools---Gene Ontology (GO) analysis and Pathway analysis---from Gene Ontology database and the KEGG database, respectively.

Gene Ontology online database was established by the Gene Ontology Consortium in 2000. The Gene Ontology project is a major bioinformatics initiative with the aim of standardizing the representation of gene and gene product attributes across species and databases. The database can be used to search or predict disease-related aberrantly expressed gene/function \[[@B10], [@B11]\]. The KEGG database has been in development by Kanehisa Laboratories since 1995. KEGG is a collection of online databases dealing with genomes, enzymatic pathways, and biological chemicals. KEGG connects known information on molecular interaction networks, such as pathways and complexes (this is the Pathway Database), information about genes and proteins generated by genome projects (including the gene database), and information about biochemical compounds and reactions (including compound and reaction databases). The higher order functional information is stored in the Pathway Database, which contains graphical representations of cellular processes, such as metabolism, membrane transport, signal transduction, and cell cycle \[[@B12]--[@B16]\].

GO analysis and Pathway analysis are two major tools based on the above two bioinformatics databases and are frequently used to analyze gene and gene function via gene Chip assay. GO analysis is more specific about single gene function, while Pathway analysis is more about networks of gene interactions in the cells, and integrating the two tools will yield better results on gene function analysis.

In this study, we used both GO analysis (based on Gene Ontology database) and Pathway analysis (based on KEGG database) to map the corresponding genomic position and function. Statistical significance of the difference between values of methylation levels for different samples/groups were assessed using Fisher and multiple comparison test with *P* \< 0.05, false discovery rate (FDR) \< 0.05 as filtering cut-off point.

3. Results {#sec3}
==========

3.1. DNA Methylation before Treatment {#sec3.1}
-------------------------------------

According to conclusion drawn from GO analysis, 1063 hypermethylated genes were identified in 25 MDS patients compared with normal control, which consisted of 2.7% of the 4 million genes being tested. The hypermethylated genes involve 156 functional pathways, including response to stimulus, regulation of transcription DNA-dependent, multicellular organismal development, DNA-dependent positive regulation of transcription, signal transduction, apoptosis, cell cycle, and DNA repair, and so forth, as listed in [Table 2](#tab2){ref-type="table"} (parts of 156 functional pathways).

Using Pathway analysis, we observed that 318 hypermethylated genes were identified in 25 MDS patients compared with control. The functions of these genes involve 46 different pathways, including pathways in cancer, Endocytosis, chemokine signaling pathway, ErbB signaling pathway, olfactory transduction, and so forth, as listed in [Table 3](#tab3){ref-type="table"} (parts of 46 functional pathways).

Consistent with multiple reports \[[@B17]--[@B24]\] and online database (<http://www.ncbi.nlm.nih.gov/gene>), our results indicate that MDS patients have aberrant DNA hypermethylation. Specifically, we confirmed that the following 27 genes, involving transcription control, signaling transduction, cell development, and adhesion, as well as cancer, are hypermethylated in MDS patients: ARNT2, E2F3, HDAC1, PIAS3, TCF7L1, TGFBR1, DCC, EPAS1, MET, WNT16, WNT6, WNT8B, FZD1, NCOA4, NFKB1, BCR, FASLG, FLT3LG, IGF1R, KIT, MAP2K1, PIK3R2, PLCG1, PLCG2, RALBP1, TRAF3, and SRC.

3.2. Karyotype and Gene Methylation {#sec3.2}
-----------------------------------

Among 25 MDS patients, normal karyotypes were observed in 12 cases, trisomy +8 was observed in 6 cases. The remaining 7 patients were cases of other type of aberrant karyotype, including 2 cases of −7, one case of 4p-, +9, dup(1q), −X/Xq-, and complex karyotype, respectively ([Table 1](#tab1){ref-type="table"}).

Compared to healthy control, as analyzed by GO analysis, the number of aberrant DNA methylation is higher in patients with normal karyotype (1656 counts) and trisomy 8 karyotype (880 counts). DNA methylation is relative low in patients with cytogenetic abnormalities other than trisomy 8 (39 counts) ([Figure 1(a)](#fig1){ref-type="fig"}). The same DNA hypermethylation pattern is observed analyzed by Pathway analysis ([Figure 1(b)](#fig1){ref-type="fig"}).

3.3. Karyotype Status after Treatment {#sec3.3}
-------------------------------------

Certain amount of blood arsenic was observed in most patients (7.6 ug/L to 35.4 ug/L) after treatment. Hematologic responses were acquired after treatment with arsenic-containing Chinese herbal formula in 14 patients that have completed treatment for 6 months, including 2 CR and 12 hematologic improvements. Of these 14 patients, no karyotype change was observed after treatment in most cases, with the exception of one case, whose karyotype changed from 46, XX \[20\], trisomy +8 signal \< 1.0% (by FISH) before treatment, to 47, XX, +8\[6\], -X\[2\]/46, XX\[23\], trisomy +8 signal \> 40% (by FISH) after treatment. We concluded that arsenic-containing Chinese herbal formula had no obvious effects on karyotype status.

3.4. Demethylation Effects of Arsenic-Containing Chinese Herbal Formula {#sec3.4}
-----------------------------------------------------------------------

Six months of treatment with arsenic-containing Chinese herbal formula significantly decreased number of methylated genes and their functional signaling pathways in MDS patients.

According to GO analysis tool, the number of hypermethylated gene decreased from 1063 to 75 after treatment. The functional pathways that involved gene hypermethylated decreased from 156 to 18 after treatment ([Table 4](#tab4){ref-type="table"}). Further analysis indicated that the methylated genes involved in multicellular organismal development, signal transduction and apoptosis were demethylated after treatment.

Analyzed by Pathway analysis tool, the number of hypermethylated gene decreased from 318 to 21 after treatment. The involved functional pathways of the hypermethylated genes decreased from 47 to 8 ([Table 5](#tab5){ref-type="table"}). The methylated genes involved in cancer signals, chemokine signaling pathway, MAPK signaling pathway, calcium signaling, and so forth, were demethylated after treatment.

Compared with multiple reports \[[@B17]--[@B24]\] and online database (<http://www.ncbi.nlm.nih.gov/gene>), our results indicate that 13 hypermethylated genes were demethylated after treatment ([Table 6](#tab6){ref-type="table"}). Of these 13 demethylated genes, WNT8B, DCC, DACT1 involve multicellular organismal development; E2F3, NCOA4, HDAC1, PIAS3, ATF3, ZBTB33, LHX9 mainly involve transcription control; FASLG, TRAF3 involve cell apoptosis; PIK3R2 mainly involves signaling transduction.

Overall, our results indicated that after treatment with arsenic-containing Chinese herbal formula, the numbers of hypermethylated genes and the involved functional pathways were significantly decreased. The methylated genes involved in MDS pathogenesis were de-methylated after treatment with arsenic-containing herbal formula.

4. Discussion {#sec4}
=============

Aberrant DNA methylation is frequently observed in the myeloid malignancies, including myelodysplastic syndrome (MDS). With most researches focusing on single gene methylation \[[@B18]--[@B24]\], the limitations of these researches are obvious regarding global DNA methylation in MDS. In this study, using global DNA methylation method (ChIP-on-chip assays), we investigated genomic wide DNA methylation level in MDS thus reveal overall methylation profiling in MDS. We also determined the effect of arsenic-containing Chinese herbal formula on karyotype and the genomic methylation level in MDS patients.

Our results indicated that among 4 million genes being tested 1063 genes were hypermethylated in MDS patients compared with control. The hypermethylated genes involve 156 functional pathways. Currently over 30 hypermethylated genes have been identified in MDS patients \[[@B17]--[@B24]\]. Confirmatively, we observed 17 of these hypermethylated genes in this study, namely FZD1, SOCS2, DKK1, DACT1, GADD45B, GADD45G, ARHGAP8, ARHGAP44, CDH7, ZBTB32, ZBTB33, ZBTB40, PAX2, ATF3, POU4F2, LHX2, and LHX9. The function of these genes is highly related to the pathogenesis of MDS.

After analyzing the correlation of DNA methylation status and karyotypes, we found that the number of genes with aberrant methylation is the highest in MDS patients with normal karyotype, higher in trisomy 8 karyotype, and relative low in patients with cytogenetic abnormalities other than trisomy 8 karyotype. Interestingly, we found that after treatment with arsenic-containing Chinese herbal formula, clinical outcome of MDS patients with normal karyotype or trisomy 8 is better than that of the patients with other cytogenetic abnormalities \[[@B5]\]. However arsenic-containing Chinese herbal formula had no effects on karyotype status of the patients.

Furthermore, after treatment with arsenic-containing Chinese herbal formula, the number of hypermethylated genes decreased from 1063 to 75; the functional pathways affected by these hypermethylated genes decreased from 156 to 18. The methylated genes involved in multicellular organismal development, signal transduction, and apoptosis were demethylated after treatment. We identified 13 genes, whose function involving in multicellular organismal development, transcription control, signal transduction, apoptosis, cell development, and adhesion, as well as pathways in cancer, had been completely demethylated after treatment. The identified 13 demethylated genes including WNT8B, DCC, DACT1, E2F3, NCOA4, HDAC1, PIAS3, ATF3, ZBTB33, LHX9, FASLG, TRAF3, and PIK3R2), are critical for pathogenesis of MDS. Our research uncovered a novel DNA demethylating activity of Realgar-containing Chinese herbal formula in the treatment of MDS.

Currently DNA hypomethylating agents like the cytidine nucleoside analogs azacitidine and decitabine are widely used for the treatment of patients with myelodysplastic syndromes. Both drugs effected DNA methyltransferase-1 depletion and DNA hypomethylation \[[@B25]--[@B28]\]. However based on detoxification process of arsenic, we reason that arsenic hypomethylates DNA in a different pathway from azacitidine. Methylation of arsenic had been recognized as a detoxification process through methyltransferase enzymes using S-adenosylmethionine as methyl donor. Therefore the observed hypomethylating effects of arsenic in this study might be due to its competitive exhaustion of methyl during detoxification process of arsenic. Details regarding this mechanism are currently under investigation in the lab.

In summary, in this study we found that aberrant DNA methylation correlates with MDS pathogenesis; the number of aberrant DNA methylation is highest in patients with normal karyotype, followed by trisomy 8 karyotype and relative low in patients with other cytogenetic abnormalities; treatment with arsenic-containing Chinese herbal formula resulted in a significant genome-wide demethylation, with no effects on karyotype status; the function of the demethylated genes is largely involved in transcription control, signal transduction, cell apoptosis, and multicellular organismal development. Our research uncovered a novel DNA demethylating activity of arsenic-containing Chinese herbal formula in the treatment of MDS.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplement Fig 1: Initial standardization of gene Chips: status before standardization (A) and after standardization (B).

Supplement Fig 2: Correlation of each pair of gene chips before standardization (A) and after standardization (B).

###### 

Click here for additional data file.
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###### 

General information of patients.

  Patient   Sex   Age   Diagnosis     Karyotype                             Blood arsenic concentration (ug/L)       IPSS    Clinical evaluation   
  --------- ----- ----- ------------- ------------------------------------- ---------------------------------------- ------- --------------------- ---------
  1\*       F     31    MDS-RCMD      47,XY,+8\[10\]                        47,XY,+8\[10\]                           7.60    Mid-risk I            Improve
  2\*       F     41    MDS-RCMD      46,XX,+8,−5\[5\]/47,XX,+8\[15\]       46,XX,+8,−5\[15\]/46,XX\[1\]             35.39   Mid-risk I            Improve
  3\*       M     31    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                              10.56   Mid-risk I            Improve
  4\*       M     23    MDS-RCMD      47,XY,+8\[8\]/46,XY\[10\]             47,XY,+8\[11\]/46,XY\[9\]                31.76   Mid-risk I            Improve
  5\*       M     41    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                              20.44   Mid-risk I            Improve
  6\*       F     25    MDS-RCMD      46,XX\[20\]                           47,XX,+8\[6\],−X\[2\]/46,XX\[23\]        19.74   Mid-risk I            Improve
  7\*       M     26    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                                      Mid-risk I            Improve
  8\*       M     34    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                                      Mid-risk I            Improve
  9\*       M     48    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                                      Mid-risk I            CR
  10\*      M     33    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                                      Mid-risk I            Improve
  11\*      M     40    MDS-RCMD      46,XY\[20\]                           46,XY\[20\]                                      Mid-risk I            Improve
  12\*      M     28    MDS-RCMD      46,XY\[24\]                           46,XY\[20\]                              11.42   Mid-risk I            Improve
  13\*      F     21    MDS-RCMD      46,XX\[20\]                           46,XX\[20\]                              18.34   Mid-risk I            CR
  14\*      F     57    MDS-RAEB I    45-46,−X/Xq-\[10\]                    45-46-C/cq-(7?,9?,x?)\[10\]/46,xx\[1\]           Mid-risk II           Improve
  15        F     31    MDS-RCMD      46,XX\[16\]                                                                            Mid-risk I             
  16        F     57    MDS-RCMD      46,XX\[20\]                                                                            Mid-risk I             
  17        F     25    MDS-RCMD      46,XX\[8\]                                                                             Mid-risk I             
  18        M     40    MDS-RCMD-RS   47,XY,+8\[6\]/46,XY\[1\]                                                               Mid-risk I             
  19        M     43    MDS-RCMD      47,XY,+8\[9\]/46,XY\[11\]                                                              Mid-risk I             
  20        M     69    MDS-RCMD      45,XY, −7\[16\]/46,XY\[3\]                                                             Mid-risk II            
  21        F     36    MDS-RAEB I    46,XX,4p-\[19\]/46,XX\[1\]                                                             Mid-risk II            
  22        M     51    MDS-RCMD      48,XY,9q-,+10,+14\[4\]/9q-,+14\[8\]                                                    Mid-risk II            
  23        F     54    MDS-RCMD      47,XX,+9\[16\]                                                                         Mid-risk II            
  24        M     34    MDS-RCMD      46,XY,dup(1q)\[20\]                                                                    Mid-risk II            
  25        F     75    MDS-RCMD      45,XX, −7\[13\]                                                                        Mid-risk II            

\*Gene methylation and karyotype were analyzed before and after treatment.

###### 

Functions of genes with hypermethylation.

  -----------------------------------------------------------------------------------------------------------------------------
  Go_id        Go_name                                                                Diffgene\   *P* value      FDR
                                                                                      \_count                    
  ------------ ---------------------------------------------------------------------- ----------- -------------- --------------
  GO:0050896   Response to stimulus                                                   51          3.16*E* − 22   2.73*E* − 19

  GO:0006355   Regulation of transcription, DNA-dependent                             141         7.10*E* − 17   3.07*E* − 14

  GO:0007275   Multicellular organismal development                                   105         2.50*E* − 16   7.23*E* − 14

  GO:0045893   Positive regulation of transcription,\                                 59          7.24*E* − 11   1.57*E* − 08
               DNA-dependent                                                                                     

  GO:0007165   Signal transduction                                                    115         1.58*E* − 10   2.73*E* − 08

  GO:0000278   Mitotic cell cycle                                                     37          5.86*E* − 08   7.84*E* − 06

  GO:0006811   Ion transport                                                          60          7.95*E* − 08   9.83*E* − 06

  GO:0006915   Apoptosis                                                              61          2.62*E* − 07   2.54*E* − 05

  GO:0007264   Small GTPase mediated signal transduction                              38          2.69*E* − 07   2.59*E* − 05

  GO:0006810   Transport                                                              59          4.52*E* − 07   3.58*E* − 05

  GO:0006357   Regulation of transcription from RNA polymerase II promoter            31          4.58*E* − 07   3.61*E* − 05

  GO:0016568   Chromatin modification                                                 26          5.63*E* − 07   4.06*E* − 05

  GO:0007049   Cell cycle                                                             42          6.84*E* − 07   4.55*E* − 05

  GO:0000122   Negative regulation of transcription from RNA polymerase II promoter   44          1.50*E* − 06   9.12*E* − 05

  GO:0006281   DNA repair                                                             33          2.47*E* − 06   1.36*E* − 04
  -----------------------------------------------------------------------------------------------------------------------------

This table shows parts of 156 category functions of genes with hypermethylation in 25 MDS patients. go_id: gene ID number in Gene Ontology database; go_name: category of function of gene; diffgene_count: number of gene methylated; *P* value: *P* \< 0.01 indicating methylation is significant; FDR: false discovery rate, *P* \< 0.05 as filter cutoff rate.

###### 

Pathways of hypermethylated genes.

  ------------------------------------------------------------------------------------------------------------------
  Path_id   Path_name                                                      Diffgene\   *P* value      FDR
                                                                           \_count                    
  --------- -------------------------------------------------------------- ----------- -------------- --------------
  5200      Pathways in cancer                                             41          2.22*E* − 05   1.15*E* − 03

  5120      Epithelial cell signaling in *Helicobacter pylori* infection   14          1.11*E* − 04   2.86*E* − 03

  3050      Proteasome                                                     10          5.40*E* − 04   7.31*E* − 03

  4144      Endocytosis                                                    26          5.83*E* − 04   7.53*E* − 03

  4062      Chemokine signaling pathway                                    24          1.20*E* − 03   9.49*E* − 03

  4666      Fc gamma R-mediated phagocytosis                               15          1.48*E* − 03   9.98*E* − 03

  4650      Natural killer cell mediated cytotoxicity                      19          1.75*E* − 03   1.03*E* − 02

  5211      Renal cell carcinoma                                           12          2.13*E* − 03   1.07*E* − 02

  5210      Colorectal cancer                                              11          2.54*E* − 03   1.09*E* − 02

  4670      Leukocyte transendothelial migration                           16          3.92*E* − 03   1.40*E* − 02

  4612      Antigen processing and presentation                            12          4.43*E* − 03   1.49*E* − 02

  4360      Axon guidance                                                  17          4.74*E* − 03   1.54*E* − 02

  4012      ErbB signaling pathway                                         13          4.91*E* − 03   1.57*E* − 02

  310       Lysine degradation                                             9           5.37*E* − 03   1.63*E* − 02

  4740      Olfactory transduction                                         38          6.37*E* − 03   1.80*E* − 02
  ------------------------------------------------------------------------------------------------------------------

This table shows parts of 46 pathways of genes with hypermethylation in 25 MDS patients. Path_id: gene ID number in KEGG database; Path_name: pathway of gene; diffgene_count: number of gene methylated in specific pathway; *P* value: *P* \< 0.01 indicating methylation is significant; FDR: false discovery rate, *P* \< 0.05 as filter cutoff rate.

###### 

Functions of genes with hypermethylation after treatment.

  --------------------------------------------------------------------------------------------------------
  Go_id        Go_name                                           Diffgene\   *P* value      FDR
                                                                 \_count                    
  ------------ ------------------------------------------------- ----------- -------------- --------------
  GO:0007596   Blood coagulation                                 13          2.09*E* − 04   2.11*E* − 02

  GO:0007088   regulation of mitosis                             3           2.36*E* − 04   2.11*E* − 02

  GO:0016337   Cell-cell adhesion                                5           5.61*E* − 04   2.55*E* − 02

  GO:0006357   Regulation of transcription from\                 8           5.72*E* − 04   2.56*E* − 02
               RNA polymerase II promoter                                                   

  GO:0006325   Chromatin organization                            3           1.11*E* − 03   3.05*E* − 02

  GO:0006890   Retrograde vesicle-mediated transport,\           3           1.54*E* − 03   3.22*E* − 02
               Golgi to ER                                                                  

  GO:0032312   Regulation of ARF GTPase activity                 2           1.64*E* − 03   3.25*E* − 02

  GO:0033690   Positive regulation of osteoblast proliferation   2           2.44*E* − 03   3.79*E* − 02

  GO:0060710   Chorioallantoic fusion                            2           2.44*E* − 03   3.79*E* − 02

  GO:0006364   rRNA processing                                   4           3.02*E* − 03   4.05*E* − 02

  GO:0043069   Negative regulation of programmed cell death      2           3.39*E* − 03   4.19*E* − 02

  GO:0015031   Protein transport                                 9           3.50*E* − 03   4.22*E* − 02

  GO:0005975   Carbohydrate metabolic process                    8           4.92*E* − 03   4.56*E* − 02

  GO:0006355   Regulation of transcription, DNA-dependent        20          5.43*E* − 03   4.65*E* − 02

  GO:0007155   Cell adhesion                                     11          5.45*E* − 03   4.66*E* − 02

  GO:0042953   Lipoprotein transport                             2           5.75*E* − 03   4.70*E* − 02

  GO:0048863   Stem cell differentiation                         2           5.75*E* − 03   4.70*E* − 02

  GO:0009395   Phospholipid catabolic process                    2           7.14*E* − 03   4.87*E* − 02
  --------------------------------------------------------------------------------------------------------

This table shows functions of genes with hypermethylation after treatment. go_id: gene ID number in Gene Ontology database; go_name: category of function of gene; diffgene_count: number of gene methylated; *P* value: *P* \< 0.01 indicating methylation is significant; FDR: false discovery rate, *P* \< 0.05 as filter cutoff rate.

###### 

Pathways of hypermethylated genes after treatment.

  Path_id   Path_name                                                      diffgene_count   *P* value      FDR
  --------- -------------------------------------------------------------- ---------------- -------------- --------------
  10        Glycolysis / Gluconeogenesis                                   4                5.97*E* − 03   3.82*E* − 02
  4622      RIG-I-like receptor signaling pathway                          4                8.21*E* − 03   3.82*E* − 02
  5164      Influenza A                                                    6                1.09*E* − 02   3.82*E* − 02
  5215      Prostate cancer                                                4                1.82*E* − 02   4.34*E* − 02
  4666      Fc gamma R-mediated phagocytosis                               4                2.35*E* − 02   4.56*E* − 02
  5131      Shigellosis                                                    3                3.68*E* − 02   4.85*E* − 02
  4964      Proximal tubule bicarbonate reclamation                        2                3.71*E* − 02   4.85*E* − 02
  5120      Epithelial cell signaling in *Helicobacter pylori* infection   3                4.90*E* − 02   4.99*E* − 02

This table shows pathways of hypermethylated genes after treatment. Path_id: gene ID number in KEGG database; Path_name: pathway of gene; diffgene_count: number of gene methylated in specific pathway; *P* value: *P* \< 0.01 indicating methylation is significant; FDR: false discovery rate, *P* \< 0.05 as filter cutoff rate.

###### 

Demethylated genes profiles after treatment.

  Go_id        Go_name                                               gene_symbol    *P* value      FDR
  ------------ ----------------------------------------------------- -------------- -------------- --------------
  GO:0007275   Multicellular organismal development                  WNT8B          1.05*E* − 09   2.69*E* − 07
  DCC          1.05*E* − 09                                          2.69*E* − 07                  
  DACT1        1.05*E* − 09                                          2.69*E* − 07                  
  GO:0045893   Positive regulation of transcription, DNA-dependent   E2F3           1.12*E* − 07   1.15*E* − 05
  NCOA4        1.12*E* − 07                                          1.15*E* − 05                  
  HDAC1        1.12*E* − 07                                          1.15*E* − 05                  
  GO:0006355   Regulation of transcription, DNA-dependent            PIAS3          3.24*E* − 06   2.08*E* − 04
  ATF3         3.24*E* − 06                                          2.08*E* − 04                  
  ZBTB33       3.24*E* − 06                                          2.08*E* − 04                  
  GO:0006915   Apoptosis                                             FASLG          2.10*E* − 05   9.76*E* − 04
  GO:0045892   Negative regulation of transcription, DNA-dependent   LHX9           2.32*E* − 05   1.04*E* − 03
  GO:0006917   Induction of apoptosis                                TRAF3          6.13*E* − 05   2.12*E* − 03
  GO:0007165   Signal transduction                                   PIK3R2         2.58*E* − 04   6.45*E* − 03

[^1]: Academic Editor: Shao Li
